560
Views
24
CrossRef citations to date
0
Altmetric
Review

Potential role of coenzyme Q10 in health and disease conditions

, , , , &
Pages 1-11 | Published online: 14 Feb 2018

References

  • Molyneux SL, Young JM, Florkowski CM, Lever M, George PM. Coenzyme Q10: is there a clinical role and a case for measurement? Clin Biochem Rev. 2008;29(2):71–82.
  • Turunen M, Olsson J, Dallner G. Metabolism and function of coenzyme Q. Biochim Biophys Acta. 2004;1660(1–2):171–199.
  • Lance J, McCabe S, Clancy RL, Pierce J. Coenzyme QIO – a therapeutic agent. Medsurg Nurs. 2012;21(6):367–371.
  • Sohet FM, Delzenne NM. Is there a place for coenzyme Q in the management of metabolic disorders associated with obesity? Nutr Rev. 2012;70(11):631–641.
  • Crozier A, Borges G. (Poly)phenolic constituents and the beneficial effects of moderate red wine consumption. J Wine Res. 2011;22(2):131–134.
  • Cain JC, Morton RA. Some minor constituents of liver oils. Biochem J. 1955;60(2):274–283.
  • Fahmy NI, Hemming FW, Morton RA, Paterson JYF, Pennock JF. Ubiquinone. Biochem J. 1958;70(1P).
  • Ramasarma T. A touch of history and a peep into the future of the lipid-quinone known as coenzyme Q and ubiquinone. Curr Sci. 2012;102(10):1459–1471.
  • Crane FL, Hatefi Y, Lester RL, Widmer C. Isolation of a quinone from beef heart mitochondria. Biochim Biophys Acta. 1957;25(1):220–221.
  • Crane FL. Discovery of ubiquinone (coenzyme Q) and an overview of function. Mitochondrion. 2007;7(Suppl):S2–S7.
  • Crane FL. The evolution of coenzyme Q. Biofactors. 2008;32(1–4):5–11.
  • Potgieter M, Pretorius E, Pepper MS. Primary and secondary coenzyme Q10 deficiency: the role of therapeutic supplementation. Nutr Rev. 2013;71(3):180–188.
  • Kommuru TR, Ashraf M, Khan MA, Reddy IK. Stability and bioequivalence studies of two marketed formulations of coenzyme Q10 in beagle dogs. Chem Pharm Bull (Tokyo). 1999;47(7):1024–1028.
  • Ikematsu H, Nakamura K, Harashima S, Fujii K, Fukutomi N. Safety assessment of coenzyme Q10 (Kaneka Q10) in healthy subjects: a double-blind, randomized, placebo-controlled trial. Regul Toxicol Pharmacol. 2006;44(3):212–218.
  • Cluis CP, Pinel D, Martin VJ. The production of coenzyme q10 in microorganisms. Subcell Biochem. 2012;64:303–326.
  • Bhagavan HN, Chopra RK. Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics. Free Radic Res. 2006;40(5):445–453.
  • Bhagavan HN, Chopra RK. Plasma coenzyme Q10 response to oral ingestion of coenzyme Q10 formulations. Mitochondrion. 2007;7(Suppl): S78–S88.
  • Lester RL, Crane FL. The natural occurrence of coenzyme Q and related compounds. J Biol Chem. 1959;234(8):2169–2175.
  • Overvad K, Diamant B, Holm L, Holmer G, Mortensen SA, Stender S. Coenzyme Q10 in health and disease. Eur J Clin Nutr. 1999; 53(10):764–770.
  • Weber C. Dietary Intake and Absorption of Coenzyme Q. Boca Raton, FL: CRC Press; 2001.
  • Chopra RK, Goldman R, Sinatra ST, Bhagavan HN. Relative bioavailability of coenzyme Q10 formulations in human subjects. Int J Vitam Nutr Res. 1998;68(2):109–113.
  • Zaghloul AA, Gurley B, Khan M, Bhagavan H, Chopra R, Reddy I. Bioavailability assessment of oral coenzyme Q10 formulations in dogs. Drug Dev Ind Pharm. 2002;28(10):1195–1200.
  • Shults CW, Flint Beal M, Song D, Fontaine D. Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson’s disease. Exp Neurol. 2004;188(2):491–494.
  • Duncan AJ, Heales SJ, Mills K, Eaton S, Land JM, Hargreaves IP. Determination of coenzyme Q10 status in blood mononuclear cells, skeletal muscle, and plasma by HPLC with di-propoxy-coenzyme Q10 as an internal standard. Clin Chem. 2005;51(12):2380–2382.
  • Steele PE, Tang PH, DeGrauw AJ, Miles MV. Clinical laboratory monitoring of coenzyme Q10 use in neurologic and muscular diseases. Am J Clin Pathol. 2004;121(Suppl):S113–S120.
  • Ziegler DM. The role of quinones in the mitochondrial electron transport system. Am J Clin Nutr. 1961;9(4):43–49.
  • Kozlov AV, Gille L, Staniek K, Nohl H. Dihydrolipoic acid maintains ubiquinone in the antioxidant active form by two-electron reduction of ubiquinone and one-electron reduction of ubisemiquinone. Arch Biochem Biophys. 1999;363(1):148–154.
  • Echtay KS, Winkler E, Klingenberg M. Coenzyme Q is an obligatory cofactor for uncoupling protein function. Nature. 2000; 408(6812):609–613.
  • Littarru GP, Tiano L, Belardinelli R, Watts GF. Coenzyme Q10, endothelial function, and cardiovascular disease. Biofactors. 2011;37(5):366–373.
  • Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics – 2014 update: a report from the American Heart Association. Circulation. 2014;129(3):e28–e292.
  • Singh RB, Niaz MA, Kumar A, Sindberg CD, Moesgaard S, Littarru GP. Effect on absorption and oxidative stress of different oral Coenzyme Q10 dosages and intake strategy in healthy men. Biofactors. 2005;25(1–4):219–224.
  • Littarru GP, Tiano L. Clinical aspects of coenzyme Q10: an update. Nutrition. 2010;26(3):250–254.
  • Tiano L, Belardinelli R, Carnevali P, Principi F, Seddaiu G, Littarru GP. Effect of coenzyme Q10 administration on endothelial function and extracellular superoxide dismutase in patients with ischaemic heart disease: a double-blind, randomized controlled study. Eur Heart J. 2007;28(18):2249–2255.
  • Bogdan C. Nitric oxide and the regulation of gene expression. Trends Cell Biol. 2001;11(2):66–75.
  • Rosenfeldt F, Hilton D, Pepe S, Krum H. Systematic review of effect of coenzyme Q10 in physical exercise, hypertension and heart failure. Biofactors. 2003;18(1–4):91–100.
  • Morisco C, Trimarco B, Condorelli M. Effect of coenzyme Q10 therapy in patients with congestive heart failure: a long-term multicenter randomized study. Clin Investig. 1993;71(8 Suppl):S134–S136.
  • Lee BJ, Yen CH, Hsu HC, Lin JY, Hsia S, Lin PT. A significant correlation between the plasma levels of coenzyme Q10 and vitamin B-6 and a reduced risk of coronary artery disease. Nutr Res. 2012;32(10):751–756.
  • Lee BJ, Huang YC, Chen SJ, Lin PT. Effects of coenzyme Q10 supplementation on inflammatory markers (high-sensitivity C-reactive protein, interleukin-6, and homocysteine) in patients with coronary artery disease. Nutrition. 2012;28(7–8):767–772.
  • Hargreaves IP. Coenzyme Q10 as a therapy for mitochondrial disease. Int J Biochem Cell Biol. 2014;49:105–111.
  • Hasegawa G, Yamamoto Y, Zhi JG, et al. Daily profile of plasma %CoQ10 level, a biomarker of oxidative stress, in patients with diabetes manifesting postprandial hyperglycaemia. Acta Diabetol. 2005;42(4):179–181.
  • Menke A, Orchard TJ, Imperatore G, Bullard KM, Mayer-Davis E, Cowie CC. The prevalence of type 1 diabetes in the United States. Epidemiology.2013;24(5):773–774.
  • Mezawa M, Takemoto M, Onishi S, et al. The reduced form of coenzyme Q10 improves glycemic control in patients with type 2 diabetes: an open label pilot study. Biofactors. 2012;38(6):416–421.
  • Hodgson JM, Watts GF, Playford DA, Burke V, Croft KD. Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. Eur J Clin Nutr. 2002;56(11):1137–1142.
  • Salles JE, Moises VA, Almeida DR, Chacra AR, Moises RS. Myocardial dysfunction in mitochondrial diabetes treated with Coenzyme Q10. Diabetes Res Clin Pract. 2006;72(1):100–103.
  • Mancuso M, Orsucci D, Volpi L, Calsolaro V, Siciliano G. Coenzyme Q10 in neuromuscular and neurodegenerative disorders. Curr Drug Targets. 2010;11(1):111–121.
  • Mischley LK, Allen J, Bradley R. Coenzyme Q10 deficiency in patients with Parkinson’s disease. J Neurol Sci. 2012;318(1–2):72–75.
  • Wadsworth TL, Bishop JA, Pappu AS, Woltjer RL, Quinn JF. Evaluation of coenzyme Q as an antioxidant strategy for Alzheimer’s disease. J Alzheimers Dis. 2008;14(2):225–234.
  • Hodges S, Hertz N, Lockwood K, Lister R. CoQ10: could it have a role in cancer management? Biofactors. 1999;9(2–4):365–370.
  • Folkers K, Osterborg A, Nylander M, Morita M, Mellstedt H. Activities of vitamin Q10 in animal models and a serious deficiency in patients with cancer. Biochem Biophys Res Commun. 1997;234(2):296–299.
  • Bliznakov EG. Effect of stimulation of the host defense system by coenzyme Q 10 on dibenzpyrene-induced tumors and infection with Friend leukemia virus in mice. Proc Natl Acad Sci U S A. 1973;70(2):390–394.
  • Fouad AA, Al-Mulhim AS, Jresat I. Therapeutic effect of coenzyme Q10 against experimentally-induced hepatocellular carcinoma in rats. Env Toxicol Pharmacol. 2013;35(1):100–108.
  • Yuvaraj S, Premkumar VG, Shanthi P, Vijayasarathy K, Gangadaran SG, Sachdanandam P. Effect of Coenzyme Q(10), Riboflavin and Niacin on Tamoxifen treated postmenopausal breast cancer women with special reference to blood chemistry profiles. Breast Cancer Res Treat. 2009;114(2):377–384.
  • Al-Bazi MM, Elshal MF, Khoja SM. Reduced coenzyme Q(10) in female smokers and its association with lipid profile in a young healthy adult population. Arch Med Sci. 2011;7(6):948–954.
  • Zita C, Overvad K, Mortensen SA, Sindberg CD, Moesgaard S, Hunter DA. Serum coenzyme Q10 concentrations in healthy men supplemented with 30 mg or 100 mg coenzyme Q10 for two months in a randomised controlled study. Biofactors. 2003;18(1–4):185–193.
  • Díaz-Castro J, Guisado R, Kajarabille N, et al. Coenzyme Q supplementation ameliorates inflammatory signaling and oxidative stress associated with strenuous exercise. Eur J Nutr. 2012;51(7):791–799.
  • Östman B, Sjödin A, Michaëlsson K, Byberg L. Coenzyme Q10 supplementation and exercise-induced oxidative stress in humans. Nutrition. 2012;28(4):403–417.
  • Singh U, Devaraj S, Jialal I. Coenzyme Q10 supplementation and heart failure. Nutr Rev. 2007;65(6 Pt 1):286–293.
  • De Pinieux G, Chariot P, Ammi-Said M, et al. Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br J Clin Pharmacol. 1996;42(3):333–337.
  • Paiva H, Thelen KM, Van Coster R, et al. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin Pharmacol Ther. 2005;78(1):60–68.
  • Caso G, Kelly P, McNurlan MA, Lawson WE. Effect of coenzyme q10 on myopathic symptoms in patients treated with statins. Am J Cardiol. 2007;99(10):1409–1412.
  • Kishi T, Watanabe T, Folkers K. Bioenergetics in clinical medicine XV. Inhibition of coenzyme Q10-enzymes by clinically used adrenergic blockers of beta-receptors. Res Commun Chem Pathol Pharmacol. 1977;17(1):157–164.
  • Engelsen J, Nielsen JD, Winther K. Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients. A randomised, double blind, placebo-crossover trial. Thromb Haemost. 2002;87(6):1075–1076.
  • Moreno-Fernandez AM, Cordero MD, Garrido-Maraver J, et al. Oral treatment with amitriptyline induces coenzyme Q deficiency and oxidative stress in psychiatric patients. J Psychiatr Res. 2012;46(3):341–345.
  • Cordero MD, Moreno-Fernandez AM, Gomez-Skarmeta JL, et al. Coenzyme Q10 and alpha-tocopherol protect against amitriptyline toxicity. Toxicol Appl Pharmacol. 2009;235(3):329–337.
  • NATURAL MEDICINES COMPREHENSIVE DATABASE. http://www.naturaldatabase.com. Accessed January 17, 2018.
  • EVIDENCE ANALYSIS LIBRARY. Available from: http://www.andeal.org.Accessed January 17, 2018.
  • Sohal RS, Forster MJ. Coenzyme Q, oxidative stress and aging. Mitochondrion. 2007;7(Suppl):S103–S111.